Valneva Reports Strong Phase III Chikungunya Vaccine Data After Merck’s Exit from Race

Data from a Phase III study showed Valneva’s chikungunya vaccine candidate VLA1553 can elicit a strong immune response and could be an effective protective option against the mosquito-borne disease caused by the chikungunya virus, the French company announced Tuesday.